A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects with Psoriatic Arthritis
Latest Information Update: 03 Dec 2023
At a glance
- Drugs Bimekizumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions
- Acronyms BE ACTIVE 2
- Sponsors UCB Biopharma
- 13 Jul 2022 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study published in the Arthritis and Rheumatology
- 05 Jul 2022 Results reporting long-term effects of bimekizumab treatment, up to 3 years on patient-reported outcome (PRO) measures, symptoms and impact of disease in patients with psoriatic arthritis from BE ACTIVE and its open-label extension published in the Rheumatology.
- 09 Nov 2021 Results from NCT02969525 and NCT03347110 assessing long-term impact of Bimekizumab treatment, up to 3 years, on pt-reported outcome measures, presented at the ACR Convergence 2021